A Randomized, Controlled Phase III Trial of Sorafenib With or Without Conventional Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma (STAH Study)
Phase of Trial: Phase III
Latest Information Update: 14 Apr 2018
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms STAH
- 14 Apr 2018 Results presented at The International Liver Congress 2018
- 27 Mar 2018 Status changed from active, no longer recruiting to completed.
- 05 Apr 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.